Regulatory Toxicology and Pharmacology

نویسندگان

  • Åke Bergman
  • Georg Becher
  • Bruce Blumberg
  • Poul Bjerregaard
  • Riana Bornman
  • Ingvar Brandt
  • Stephanie C. Casey
  • Heloise Frouin
  • Linda C. Giudice
  • Jerrold J. Heindel
  • Taisen Iguchi
  • Susan Jobling
  • Karen A. Kidd
  • Andreas Kortenkamp
  • Monica Lind
  • Derek Muir
  • Roseline Ochieng
  • Erik Ropstad
  • Peter S. Ross
  • Niels Erik Skakkebaek
  • Jorma Toppari
  • Laura N. Vandenberg
  • Tracey J. Woodruff
چکیده

We present a detailed response to the critique of “State of the Science of Endocrine Disrupting Chemicals 2012” (UNEP/WHO, 2013) by financial stakeholders, authored by Lamb et al. (2014). Lamb et al.'s claim that UNEP/WHO (2013) does not provide a balanced perspective on endocrine disruption is based on incomplete and misleading quoting of the report through omission of qualifying statements and inaccurate description of study objectives, results and conclusions. Lamb et al. define extremely narrow standards for synthesizing evidence which are then used to dismiss the UNEP/WHO 2013 report as flawed. We show that Lamb et al. misuse conceptual frameworks for assessing causality, especially the BradfordeHill criteria, by ignoring the fundamental problems that exist with inferring causality from empirical observations. We conclude that Lamb et al.'s attempt of deconstructing the UNEP/WHO (2013) report is not particularly erudite and that their critique is not intended to be convincing to the scientific community, but to confuse the scientific data. Consequently, it promotes misinterpretation of the UNEP/ WHO (2013) report by non-specialists, bureaucrats, politicians and other decision makers not intimately familiar with the topic of endocrine disruption and therefore susceptible to false generalizations of bias

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Comments on the safety assessment of decamethylcyclopentasiloxane (D5) published in regulatory toxicology and pharmacology, 2017, 83:117-118.

This letter is in response to the summary of the safety assessment of the Scientific Committee on Consumer Safety (SCCS) on decamethylcyclopentasiloxane (D5) in cosmetic products published (SCCS & Rousselle, 2017) and the opinion (SCCS, 2017). We have been asked by the Silicones Environmental, Health and Safety Center of the American Chemistry Council to provide comments given that SCCS (2017) ...

متن کامل

Pharmacology and Toxicology of Leflunomide

Leflunomide (LEF), used for rheumatoid arthritis, inhibits dihydro-orotate dehydrogenase (DHODH) and tyrosine kinase (TK) enzymes and has anti-inflammatory, lymphocyte proliferation regulatory, immunosuppression and chondroprotective effects. The most common adverse effects are gastrointestinal disorders, weight loss, hypertension, skin infection, and neurological and hematological toxicity. It...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2015